Engineering cord blood to improve engraftment after cord blood transplant
نویسندگان
چکیده
منابع مشابه
How to Improve Cord Blood Engraftment?
Various factors make cord blood (CB) a significant source of hematopoietic stem cells (HSCs), including ease of procurement and lack of donor attrition, with the ability to process and store the donor cells long term. Importantly, high proliferative potential of the immature HSCs allows one log less use of cells compared to bone marrow or peripheral blood stem cells. As total nucleated cell (TN...
متن کاملCurrent Strategies to Improve Engraftment in Cord Blood Transplantation
Umbilical cord blood (UCB) remains an important alternative source of hematopoietic stem cells (HSC) for allogeneic transplantation when suitable HLA-matched donors are unavailable. Cord blood (CB) offers many benefits including rapid availability, absence of risk to the donor, and a low incidence of graft-versus-host disease. However, although the overall survival of patients receiving unrelat...
متن کاملCord Blood
Stem cells are naïve or master cells. This means they can transform into special 200 cell types as needed by body, and each of these cells has just one function. Stem cells are found in many parts of the human body, although some sources have richer concentrations than others. Some excellent sources of stem cells, such as bone marrow, peripheral blood, cord blood, other tissue stem cells and ...
متن کاملInm-9: Cord Blood Banks and Cord Blood Donors Selection
Cord blood is a sample of blood taken from a newborn baby's umbilical cord.Cord blood is collected because it is rich in stem cells content, such as hematopoietic cells, which can be used to treat hematopoietic and genetic disorders. Cord Blood Transplantation has been used in the treatment of over 80 diseases, including leukemia, lymphoma and anemia. Advantages of Cord Blood Treatment: • ...
متن کاملTransplantation of cord blood stem cells for treating hematologic diseases and strategies to improve engraftment
Umbilical cord blood (CB) offers an alternative source of hematopoietic stem cells (HSCs) to treat patients with malignant and non malignant hematologic diseases, such as leukemia, lymphoma, myeloma, Fanconi anemia, myelodysplasia and sickle cell anemia [1]. Umbilical CB contains a low cell dose, and the first transplantation CB was performed in children with Fanconi anemia, by Gluckman and col...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stem Cell Investigation
سال: 2017
ISSN: 2313-0792
DOI: 10.21037/sci.2017.05.01